PACCAR Increases Regular Quarterly Dividend

BELLEVUE, Wash.--(BUSINESS WIRE)-- PACCAR Inc’s Board of Directors today approved an increase of 10% in the regular quarterly cash dividend from thirty cents ($.30) per share to thirty-three cents ($.33) per share. The dividend will be payable on March 5, 2025, to stockholders of record at the close of business on February 12, 2025.

Mark Pigott, executive chairman, shared, “PACCAR has generated excellent shareholder returns and profitability, for decades, due to its leadership in premium quality vehicles and aftermarket services. PACCAR has delivered annual dividends, including regular quarterly and extra cash dividends, totaling approximately 50% of net income for many years. PACCAR’s shareholders have earned returns that have exceeded the S&P 500 index for the last 20 years.”

Preston Feight, chief executive officer, commented, “PACCAR’s excellent global profitability is benefiting from the success of industry-leading Kenworth, Peterbilt and DAF trucks, geographic expansion, and technology-enabled aftermarket solutions at PACCAR Parts and PACCAR Financial Services. PACCAR’s trucks and transportation solutions are enhancing customers’ operating performance.”

PACCAR is a global technology leader in the design, manufacture and customer support of high-quality light-, medium- and heavy-duty trucks under the Kenworth, Peterbilt and DAF nameplates. PACCAR also designs and manufactures advanced powertrains, provides financial services and information technology, and distributes truck parts related to its principal business. PACCAR shares are listed on the NASDAQ Stock Market, symbol PCAR. Its homepage is www.paccar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241209650966/en/

Ken Hastings
[email protected]
(425) 468-7530

Source: PACCAR Inc

You May Also Be Interested In

• Azul Announces AI4J: The AI Leadership Summit for Scaling Enterprise AI
• Fortreum Launches AI-Native CMMC Assessment Readiness Review
• Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument